Enterprise Value

-3.201M

Cash

10.39M

Avg Qtr Burn

-7.059M

Short % of Float

2.26%

Insider Ownership

43.04%

Institutional Own.

8.15%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Ameluz (aminolevulinic acid hydrochloride) Details
BCC (basal cell carcinoma), AK (actinic keratosis)

Approved

Quarterly sales

Ameluz® Details
Actinic keratosis

Phase 3

Data readout

Phase 2

Data readout

Phase 1

Update